ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
36.26
0.00%
US Tech 100
19,896.80
0.26%
S&P 500
5,649.28
0.32%
US Dollar vs CAD
1.37033
0.18%
Bitcoin
63,975.89
-1.35%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTAW)

  7. Pasithea Therapeutics Corporation (KTTAW) News

KTTAW

Pasithea Therapeutics (KTTAW)

Pasithea Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KTTAW
DateTimeSourceHeadlineSymbolCompany
06/13/20245:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAWPasithea Therapeutics Corporation
05/28/20248:05AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAWPasithea Therapeutics Corporation
05/28/20248:00AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAWPasithea Therapeutics Corporation
05/28/20245:59AMGlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
05/14/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAWPasithea Therapeutics Corporation
04/29/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
04/24/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAWPasithea Therapeutics Corporation
02/13/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
01/08/20246:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAWPasithea Therapeutics Corporation
01/02/20247:35AMGlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAWPasithea Therapeutics Corporation
12/28/20234:00PMGlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAWPasithea Therapeutics Corporation
12/19/20234:19PMGlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
12/11/20237:01AMGlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAWPasithea Therapeutics Corporation
11/29/20233:27PMGlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAWPasithea Therapeutics Corporation
11/29/20236:59AMGlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAWPasithea Therapeutics Corporation
11/09/20236:59AMGlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAWPasithea Therapeutics Corporation
09/14/20237:30AMGlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAWPasithea Therapeutics Corporation
09/07/20233:14PMGlobeNewswire Inc.Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
08/01/20236:59AMGlobeNewswire Inc.Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviNASDAQ:KTTAWPasithea Therapeutics Corporation
07/20/20237:43AMGlobeNewswire Inc.Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashNASDAQ:KTTAWPasithea Therapeutics Corporation
07/20/20237:40AMGlobeNewswire Inc.Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.NASDAQ:KTTAWPasithea Therapeutics Corporation
06/30/20238:28AMGlobeNewswire Inc.Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsNASDAQ:KTTAWPasithea Therapeutics Corporation
06/29/20237:29AMGlobeNewswire Inc.Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
06/06/20233:30PMGlobeNewswire Inc.Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.NASDAQ:KTTAWPasithea Therapeutics Corporation
06/01/20236:57AMGlobeNewswire Inc.Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
05/03/20237:26AMGlobeNewswire Inc.Pasithea Therapeutics to Participate in EF Hutton Inaugural Global ConferenceNASDAQ:KTTAWPasithea Therapeutics Corporation
03/02/20237:00AMGlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual MeetingNASDAQ:KTTAWPasithea Therapeutics Corporation
02/23/20237:00AMGlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)NASDAQ:KTTAWPasithea Therapeutics Corporation
02/16/20236:30AMGlobeNewswire Inc.Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine AwardNASDAQ:KTTAWPasithea Therapeutics Corporation
01/18/20237:00AMGlobeNewswire Inc.Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004NASDAQ:KTTAWPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTAW

Your Recent History

NASDAQ
KTTAW
Pasithea Therapeutics
LSE
CPP
Cppgroup
LSE
EMV
Ishr Em Mv
LSE
TUNG
Tungsten
NYSE
AI
C3 AI
NASDAQ
GEVO
Gevo
LSE
AXN
Alexon
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved